

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3868587

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>SEQUENCE:</b>	4
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GLENVEIGH PHARMACEUTICALS, LLC	07/19/2015
CDA ROYALTY INVESTORS, LLC	07/19/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	VELO BIO, LLC
<b>Street Address:</b>	9001 AERIAL CENTER PARKWAY, SUITE 110
<b>Internal Address:</b>	AERIAL CENTER EXECUTIVE PARK
<b>City:</b>	MORRISVILLE
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	27560
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	13372151
<b>Application Number:</b>	12849651
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)778-2201
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	202-955-1500
<b>Email:</b>	ccurrie@hunton.com
<b>Correspondent Name:</b>	HUNTON & WILLIAMS LLP
<b>Address Line 1:</b>	2200 PENNSYLVANIA AVENUE, N.W.
<b>Address Line 2:</b>	INTELLECTUAL PROPERTY DEPARTMENT
<b>Address Line 4:</b>	WASHINGTON, D.C. 20037-1701
<b>ATTORNEY DOCKET NUMBER:</b>	78690.000207
<b>NAME OF SUBMITTER:</b>	CHRISTOPHER J. NICHOLS
<b>SIGNATURE:</b>	/CHRISTOPHER J. NICHOLS/
<b>DATE SIGNED:</b>	05/11/2016
<b>Total Attachments: 10</b>	

source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page1.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page2.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page3.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page4.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page5.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page6.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page7.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page8.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page9.tif  
source=Assn4GLENVEIGH-CDA2VELOAssignment2015-07-19#page10.tif

## **PATENT ASSIGNMENT AGREEMENT**

**THIS PATENT ASSIGNMENT AGREEMENT** is made and entered:

**BY AND AMONG:**           **GLENVEIGH PHARMACEUTICALS, LLC**, a Delaware limited liability company ("Glenveigh"),

**CDA ROYALTY INVESTORS, LLC**, a Delaware limited liability company ("CDA", each of CDA and Glenveigh is sometimes referred to as an "Assignor" and collectively as the "Assignors"),

**AND:**                       **VELO BIO, LLC**, a Delaware limited liability company (the "Assignee")

### **WITNESSETH**

**WHEREAS**, each Assignor has agreed that it will assign to Assignee all of its right, title and interest in and to all of the patents and patent applications listed in Schedule 1 attached hereto and incorporated herein by reference (the "Patents"); and

**WHEREAS**, Assignee is desirous of acquiring all right, title, and interest in and to the Patents, and Assignee has agreed to assume all of Assignors' right, title and interest in and to the Patents.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1.     Assignment and Assumption. Assignors hereby sell and irrevocably assign transfer and convey (the "Assignment") to Assignee and Assignee's successors, assigns and other legal representatives all of Assignors' right, title and interest in and to, and Assignee assumes all of Assignors' right, title and interest in and to, (i) the Patents; (ii) any corresponding U.S. and/or foreign patent applications that will be filed claiming priority to the Patents, including, without limitation, continuation applications, continuation-in-part applications, and divisional applications, (iii) any patents which may issue from any of the foregoing and any patents which may be reissued, re-examined or extended therefrom (all intellectual property described in clauses (ii) and (iii), the "Additional Patent Rights"); and (iv) all rights to sue and to otherwise recover damages for past infringements with respect to the Patents or to the Additional Patent Rights. Each and every of the foregoing rights, titles and interests herein are assigned to be held and enjoyed by Assignee and its successors, assigns and other legal representatives, as the same would have been held and enjoyed by each Assignor had this assignment not been made.

2.     Recordation. Assignors hereby authorize the U.S. Patent and Trademark Office, and, as appropriate, the corresponding officials in any patent office around the world, to record Assignee as the owner of the Patents and the Additional Patent Rights, and issue in accordance with this Patent Assignment Agreement all registrations of such Patents and Additional Patent

Rights and all applications for any of the same, which are assigned to Assignee by this Patent Assignment Agreement or which relate to the subject matter so assigned.

3. Assistance. Each Assignor shall provide Assignee and its successors, assigns or other legal representatives, reasonable cooperation and assistance at Assignee's or its successors, assigns or other legal representatives' request and expense (including the execution and delivery of any and all affidavits, declarations, oaths, exhibits, assignments, powers of attorney or other documentation as may be reasonably required): (i) in the preparation and prosecution of any applications covering the inventions assigned herein; (ii) in the prosecution or defense of any interference, opposition, reexamination, reissue, infringement or other proceedings that may arise in connection with any of the patent rights assigned herein, including, but not limited to, testifying as to any facts relating to the patent rights assigned herein and this Assignment; (iii) in obtaining any additional patent protection that Assignee may deem appropriate which may be secured under the laws now or hereafter in effect in the U.S. or any other country; and (iv) in the implementation or perfection of this Assignment throughout the world or as may be reasonably necessary to more fully and effectively effectuate the purposes of this Patent Assignment Agreement.

4. Assignor Unavailability. Where Assignee is unable because of any Assignor's unavailability, dissolution or for any other reason, to secure such Assignor's signature to apply for or to pursue any application for, or recordal of assignment of, any U.S. or foreign patents or patent applications, then such Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney in fact, to act for and in such Assignor's behalf and stead to execute and file and pursue any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents and the recordal of assignment thereof with the same legal force and effect as if executed by such Assignor.

5. Counterparts. This Patent Assignment Agreement may be executed in counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument.

**IN WITNESS WHEREOF**, each Assignor has caused one of its authorized representatives to hereunder set his hand on the date shown below, and Assignee has caused one of its authorized representatives to hereunder set his hand on the date shown below to signify its acceptance of this Patent Assignment Agreement.

[Signature pages follow]

IN WITNESS WHEREOF, the parties have caused this Patent Assignment Agreement to be signed by a duly authorized representative to be effective as of July 20, 2015.

ASSIGNOR

GLENVEIGH PHARMACEUTICALS, LLC

By: C. David Adair

Printed Name: C. David Adair, M.D.

Title: President


State of TENNESSEE )  
County of HAMILTON ) ss.

On July 20, 2015, before me, Nancy R. Rose, Notary Public, personally appeared C. David Adair, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

Nancy R. Rose  
Signature of Notary Public

My Commission Expires: June 22, 2016  
My Commission Expires: \_\_\_\_\_



**ASSIGNOR**

**CDA ROYALTY INVESTORS, LLC**

By: *[Signature]*

Printed Name: Gary Brunvall PO

Title: president


State of Tennessee )  
 County of Hamilton ) ss

On July 21, 2015, before me, Lisa Cox Moore, Notary Public, personally appeared Gary Brunvall, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

*[Signature]*  
 Signature of Notary Public


My Commission Expires: 06/06/2017



Place Notary Seal Above

**ASSIGNEE**


VELO BIO, LLC

By:   
Stephen E. Butts  
Manager

State of North Carolina )  
County of Wake ) ss.

On 7-19-2015, before me, Bruce Friend, Notary Public, personally appeared Stephen E Butts, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

  
Signature of Notary Public

**Bruce Friend**  
**NOTARY PUBLIC**  
**WAKE COUNTY, NC**

Place Notary Seal Above

My Commission Expires: 9-17-2017

Schedule 1 to Patent Assignment Agreement

Serial No./ Patent No.	Country	Title	Inventor(s)	Filing Date	Priority	Next Action/ Status
10/202,957 7,402,313	United States of America	Method For Controlling Preeclampsia And Eclampsia	Charles David ADAIR	July 25, 2002	Priority to	Issued as Patent No. 7,402,313 on July 22, 2008
11/317,378 7,794,716 (CIP)	United States of America	Antibody Composition And Passive Immunization Against Pregnancy-Induced Hypertension	Charles David ADAIR	December 23, 2005	Priority to 10/202,957 filed July 25, 2002	Issued as Patent No. 7,794,716. on September 14, 2010
12/849,651 8,119,134 (DIV)	United States of America	Method Of Extending Pregnancy In Patients Exhibiting At Least One Symptom Of Preeclampsia And Eclampsia	Charles David ADAIR	August 3, 2010	Priority to 10/202,957 filed July 25, 2002	Issued as Patent No. 8,119,134 on February 21, 2012

**PATENT**

**REEL: 038550 FRAME: 0677**



Serial No./Patent No.	Country	Title	Inventor(s)	Filing Date	Priority	Next Action/ Status
13/372,151 8,828,386 (CON)	United States of America	Method Of Extending Pregnancy By Reducing IVH In Patients Exhibiting At Least One Symptom Of Preeclampsia And Eclampsia	Charles David ADDAIR	February 13, 2012	Priority to 10/202,957 filed July 25, 2002	Issued as Patent No. 8,828,386. on September 9, 2014
03771818.6 1519746	EUROPE, AUSTRIA, BELGIUM, DENMARK, FRANCE, GERMANY, IRELAND, ITALY, NETHERLANDS, UNITED KINGDOM, SPAIN, SWITZERLAND	Use Of Digoxin Immune Fab For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADDAIR	July 24, 2003	Priority to US2003/23235 filed July 24, 2003	Granted as Patent No. 1519746 on July 15, 2009
03817859.1 ZL03817859.1	CHINA	Use Of Digoxin Immune Fab (Ovine) For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADDAIR	July 24, 2003	Priority to US2003/23235 filed July 24, 2003	Granted as Patent No. ZL03817859.1 on June 13, 2012

**PATENT**

**REEL: 038550 FRAME: 0678**

Serial No./Patent No.	Country	Title	Inventor(s)	Filing Date	Priority	Next Action/ Status
05108036.4 1075838	HONG KONG	Use Of Digoxin Immune Fab (Ovine) For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADAIR	September 14, 2005	Priority to 03771818.6 filed July 24, 2003	Granted as Patent No. 1075838 on October 30, 2009
2003254159 2003254159	AUSTRALIA	Use Of Digoxin Immune Fab (Ovine) For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADAIR	July 24, 2003	Priority to US2003/23235 filed July 24, 2003	Granted as Patent No. 2003254159 on January 7, 2010
PA/A/2005/001053 269982	MEXICO	Use Of Digoxin Immune Fab (Ovine) For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADAIR	July 24, 2003	Priority to US2003/23235 filed July 24, 2003	Granted as Patent No. 269982 on September 10, 2009

**PATENT**

**REEL: 038550 FRAME: 0679**

Serial No./Patent No.	Country	Title	Inventor(s)	Filing Date	Priority	Next Action/ Status
2005/00732 2005/00732	SOUTH AFRICA	Use Of Digoxin Immune Fab (Ovine) For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADAIR	July 24, 2003	Priority to US2003/23235 filed July 24, 2003	Granted as Patent No. 2005/00732 on March 29, 2006
2004-524798 5202789	JAPAN	Use Of Digoxin Immune Fab (Ovine) For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADAIR	July 24, 2003	Priority to US2003/23235 filed July 24, 2003	Granted as Patent No. 5202789 on February 22, 2103
20051001	NORWAY	Use Of Digoxin Immune Fab (Ovine) For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADAIR	July 24, 2003	Priority to US2003/23235 filed July 24, 2003	Granted; Issuance Pending

**PATENT**

**REEL: 038550 FRAME: 0680**

Serial No./Patent No.	Country	Title	Inventor(s)	Filing Date	Priority	Next Action/ Status
2492858	CANADA	Use Of Digoxin Immune Fab (Ovine) For The Regulation Of Sodium/Potassium Atpase Activity In Preeclamptic And Eclamptic Patients	Charles David ADAIR	July 24, 2003	Priority to US2003/23235 filed July 24, 2003	Pending
US2014/030623	PCT	Method for Treating Eclampsia and Preeclampsia	Charles David ADAIR	March 17, 2014	Priority to 61/799,438 Filed March 15, 2013	Pending Published as WO 2014/145797 on September 18, 2014
62/142,936 [Provisional]	US	Method for Treating Intraventricular Hemorrhage in Neonates	Charles David ADAIR	April 3, 2015		Pending

PATENT

REEL: 038550 FRAME: 0681

RECORDED: 05/11/2016